// App-Quantinova.ai

e21001 : An observational study of concomitant immunotherapies and denosumab in patients with advanced melanoma or lung cancer.

Researchers

Presenter

  • Alexander Liede

Principal Investigators

  • Rohini K Hernandez

  • Sally W Wade

  • Ronghai Bo

  • Elizabeth Ahern

  • William C Dougall

  • Mark J Smyth

Medical Centers

  • Amgen Inc, South San Francisco, CA

  • Amgen Inc, Thousand Oaks, CA

  • Wade Outcomes Research and Consulting, Salt Lake City, UT

  • Chiltern International Inc., Wilmington, NC

  • QIMR Berghofer Medical Research Institute, Brisbane, Sydney, Australia

  • QIMR Berghofer Medical Research Institute, Brisbane, Sydney, Australia

Locations

  • United States

  • Australia

Companies

  • Amgen Inc.

  • Wade Outcomes Resear

  • Chiltern Internation

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Cytotoxic T-lymphocyte-associated protein 4

Drug/Treatment

  • Pembrolizumab

  • Ipilimumab

  • Nivolumab

  • Denosumab

Outcome

  • N/A

Study Design

  • Observational

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved